Ilia I. Ouspenski

Array ( [id] => 14594199 [patent_doc_number] => 10350276 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-07-16 [patent_title] => Single dose administration of factor VIIa [patent_app_type] => utility [patent_app_number] => 16/214996 [patent_app_country] => US [patent_app_date] => 2018-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4221 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16214996 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16369086 [patent_doc_number] => 10800827 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-10-13 [patent_title] => Insulin receptor partial agonists [patent_app_type] => utility [patent_app_number] => 16/199774 [patent_app_country] => US [patent_app_date] => 2018-11-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 33177 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16199774 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16428311 [patent_doc_number] => 10828372 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-11-10 [patent_title] => Compositions and methods for the inhibition of fibrosis [patent_app_type] => utility [patent_app_number] => 16/186864 [patent_app_country] => US [patent_app_date] => 2018-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 40 [patent_no_of_words] => 16265 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16186864 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18620434 [patent_doc_number] => 11753462 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-09-12 [patent_title] => Highly oriented collagen fibril bundle and method of producing same [patent_app_type] => utility [patent_app_number] => 16/762183 [patent_app_country] => US [patent_app_date] => 2018-11-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 12226 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16762183 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14497961 [patent_doc_number] => 20190192635 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-27 [patent_title] => COMBINATION OF AN INSULIN AND A GLP-1-AGONIST [patent_app_type] => utility [patent_app_number] => 16/165837 [patent_app_country] => US [patent_app_date] => 2018-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13568 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16165837 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16913973 [patent_doc_number] => 20210187065 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-24 [patent_title] => PHARMACEUTICAL COMPOSITION FOR TREATING RETINAL DYSTROPHIES, COMPRISING NKX3.2 AND FRAGMENT THEREOF AS ACTIVE INGREDIENTS [patent_app_type] => utility [patent_app_number] => 17/273546 [patent_app_country] => US [patent_app_date] => 2018-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7813 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17273546 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16397300 [patent_doc_number] => 20200338158 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-29 [patent_title] => Therapeutic Drug for Non-Alcoholic Fatty Liver Disease [patent_app_type] => utility [patent_app_number] => 16/757067 [patent_app_country] => US [patent_app_date] => 2018-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15305 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16757067 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16204876 [patent_doc_number] => 20200237866 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-30 [patent_title] => Combination of AS1411 and SAPC-DOPS for the Treatment of Glioblastoma Multiforme [patent_app_type] => utility [patent_app_number] => 16/756247 [patent_app_country] => US [patent_app_date] => 2018-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4131 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16756247 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18187542 [patent_doc_number] => 11578111 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-02-14 [patent_title] => Porcine G-CSF variants and their uses [patent_app_type] => utility [patent_app_number] => 16/754357 [patent_app_country] => US [patent_app_date] => 2018-10-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4119 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16754357 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13837511 [patent_doc_number] => 20190022240 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-24 [patent_title] => Design of pH-Sensitive Oligopeptide Complexes For Drug Release Under Mildly Acidic Conditions [patent_app_type] => utility [patent_app_number] => 16/152226 [patent_app_country] => US [patent_app_date] => 2018-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6847 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16152226 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16312323 [patent_doc_number] => 20200291061 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-17 [patent_title] => METHOD FOR PRODUCING PEPTIDE COMPOUND [patent_app_type] => utility [patent_app_number] => 16/753001 [patent_app_country] => US [patent_app_date] => 2018-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28870 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 142 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16753001 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16389434 [patent_doc_number] => 20200330375 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-22 [patent_title] => URETHRAL STENOSIS TREATMENT AGENT AND URETHRAL STENOSIS TREATMENT METHOD [patent_app_type] => utility [patent_app_number] => 16/753592 [patent_app_country] => US [patent_app_date] => 2018-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6856 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16753592 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14072307 [patent_doc_number] => 20190085041 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-21 [patent_title] => SECRETORY PROTEIN [patent_app_type] => utility [patent_app_number] => 16/145251 [patent_app_country] => US [patent_app_date] => 2018-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10318 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 225 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16145251 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16282658 [patent_doc_number] => 20200276260 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-03 [patent_title] => USE OF PEPTIDES AS THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES AND BONE DISEASES [patent_app_type] => utility [patent_app_number] => 16/645957 [patent_app_country] => US [patent_app_date] => 2018-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5336 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16645957 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16282658 [patent_doc_number] => 20200276260 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-03 [patent_title] => USE OF PEPTIDES AS THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES AND BONE DISEASES [patent_app_type] => utility [patent_app_number] => 16/645957 [patent_app_country] => US [patent_app_date] => 2018-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5336 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16645957 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16282658 [patent_doc_number] => 20200276260 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-03 [patent_title] => USE OF PEPTIDES AS THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES AND BONE DISEASES [patent_app_type] => utility [patent_app_number] => 16/645957 [patent_app_country] => US [patent_app_date] => 2018-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5336 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16645957 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14230545 [patent_doc_number] => 20190127445 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-02 [patent_title] => SUCCINIMIDE-ACTIVATED NITROXYL COMPOUNDS AND METHODS FOR THE USE THEREOF FOR NITROXYLATION OF PROTEINS [patent_app_type] => utility [patent_app_number] => 16/131487 [patent_app_country] => US [patent_app_date] => 2018-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14315 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16131487 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16282658 [patent_doc_number] => 20200276260 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-03 [patent_title] => USE OF PEPTIDES AS THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES AND BONE DISEASES [patent_app_type] => utility [patent_app_number] => 16/645957 [patent_app_country] => US [patent_app_date] => 2018-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5336 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16645957 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16108193 [patent_doc_number] => 20200206119 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-02 [patent_title] => KERATIN HYDROLYSATE FOR ORAL COSMETIC USE [patent_app_type] => utility [patent_app_number] => 16/643045 [patent_app_country] => US [patent_app_date] => 2018-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6665 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16643045 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16108193 [patent_doc_number] => 20200206119 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-02 [patent_title] => KERATIN HYDROLYSATE FOR ORAL COSMETIC USE [patent_app_type] => utility [patent_app_number] => 16/643045 [patent_app_country] => US [patent_app_date] => 2018-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6665 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16643045 [rel_patent_id] =>[rel_patent_doc_number] =>)